

**Table S1.** Summary of molecular findings and clinical features in females with *NAA10* variants.

Reference	Cheng et al. 2019	Bader et al. 2020	Sauzier et al. 2016, Sidhu et al. 2017, Cheng et al. 2019 <b>Our case</b>	Cheng et al. 2019	Cheng et al. 2019	Popp et al. 2015	McTiernan et al. 2018	Sauzier et al. 2016	Cheng et al. 2019	Thevenon et al. 2016	Sauzier et al. 2016, Cheng et al. 2019	Cheng et al. 2019	Total	
<i>NAA10</i> mu- tation	Leu11Arg	His16Pro	Arg83Cys	Ala87Ser	Ala104Asp	Val107Phe	Val111Gly	Arg116Trp	Leu121Val	Phe128Ile	Phe128Leu	Met147Thr	12	
CADD score	32	28.6	28.9	25.4	27.6	26.1	28.3	24.3	25.8	27.9	23.4	24.0		
Functional studies	reduction in NatA cata- lytic activity	impaired NatA com- plex for- mation	clear reduction (60%) in catalytic activity; enhance catalytic activity (Cheng et al. 2019)	NA	reduction in NatA catalytic activity	nearly abol- ished enzym- atic activity	decreased stab- ility, NatA cata- lytic activity un- changed	very mild re- duction in cat- alytic activity	NA	decreased sta- bility, near loss activity <td>decreased sta- bility, near loss activity (&gt;90%)</td> <td>decreased sta- bility, near loss activity (&gt;90%)</td> <td>very mild re- duction in cat- alytic activity</td> <td></td>	decreased sta- bility, near loss activity (>90%)	decreased sta- bility, near loss activity (>90%)	very mild re- duction in cat- alytic activity	
Patients	1	1	20	3	1	1	1	1	2	1	3	1	36	
Inheritance	NA	<i>de novo</i>	<i>de novo</i> (19/20), MGM (1/20)	<i>de novo</i> (3/3)	<i>de novo</i>	<i>de novo</i>	<i>de novo</i>	<i>de novo</i>	(1/2), NA (1/2)	<i>de novo</i>	<i>de novo</i>	<i>de novo</i>	<i>de novo</i> (33/36)	
X-inactiva- tion	NA	skewed	random (1/20), NA (17/20), 92% (1/20), 100% (1/20)	NA (3/3)	NA	random	random	random	NA(2/2)	random	random (1/3), NA (2/3)	NA		
Feeding dif- ficulties			14/20	2/3	+				1/2		1/3	+	20/36	
Short stature	+		10/20	1/3		+			1/2	+	2/3		17/36	
Microceph- aly	+		11/20			+					1/3	+	15/36	
Facial Dys- morphism	+		14/20	2/3		+			1/2	+	2/3		22/36	
NDD/ ID	+	+	20/20	3/3	+	+	+	+	2/2	+	3/3	+	36/36	
Seizures			5/20	2/3							2/3		9/36	
Muscular hypotonia	+		10/20	2/3		+		+	1/2	+	1/3		18/36	
Neuropathy			1/20										1/36	
Movement disorder			4/20	1/3	+						1/3		7/36	
Brain imag- ing anom- alies	+	+	9/20	2/3		+ (mild)		+ (thin CC, di- lated LV)		+	3/3	+	20/36	
NDD		autism	8/20 autism	1/3 (au- tism, ADHD)	autism, ADHD	autism		ADHD, DCD	1/2 autism				15/36	

Behavioural abnormalities		7/20		+		1/2			9/36
Cardiac anomalies		10/20		+		+	+	1/3	14/36
Eye abnormalities	+	+	14/20	1/3	+	+		1/3	22/36
Genitourinary system abnormalities		2/20							2/36
Skeletal system abnormalities	+	10/20	1/3	+	+ (large fontanels, delayed bone age)	1/2		1/3	16/36
Ear abnormalities		3/20	1/3	+					5/36
GI tract abnormalities		5/20							
Skin abnormalities		4/20							4/36
Other	sleep disorder		sleep disorder		bruxism				